Guest guest Posted April 23, 2009 Report Share Posted April 23, 2009 From Medscape Medical News Laurie Barclay, MD Zoledronic Acid Infusion Effective for Bone Loss Linked With Glucocorticoid Use April 20, 2009 — A single 5-mg intravenous infusion of zoledronic acid was at least as effective and more acceptable to patients than 5 mg of oral risedronate daily to prevent and treat glucocorticoid-related bone loss, according to the results of a 1-year, noninferiority, double-blind, double-dummy, randomized controlled trial reported in the April 10 issue of The Lancet. " Persistent use of glucocorticoid drugs is associated with bone loss and increased fracture risk, " write M. Reid, MD, from the University of Aberdeen in Aberdeen, United Kingdom, and colleagues from the HORIZON investigators. " Concurrent oral bisphosphonates increase bone mineral density and reduce frequency of vertebral fractures, but are associated with poor compliance and adherence. We aimed to assess whether one intravenous infusion of zoledronic acid was non-inferior to daily oral risedronate for prevention and treatment of glucocorticoid-induced osteoporosis. " ********************************* Read the full article here: http://www.medscape.com/viewarticle/701618 Not an MD Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.